{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sinusitis/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"5f63c8f8-0eaa-5fe0-b473-2d5e3aef00d1","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field c53c03da-9c84-4063-b6e5-a8e800b3d92c --><h2>Clarithromycin</h2><!-- end field c53c03da-9c84-4063-b6e5-a8e800b3d92c -->","summary":"","htmlStringContent":"<!-- begin item 53559b7e-edf4-4882-acae-a8e800b3d630 --><!-- end item 53559b7e-edf4-4882-acae-a8e800b3d630 -->","topic":{"id":"6d2333af-675d-5bf3-8f7d-21404b5f0aa9","topicId":"251eec02-9620-4893-97bb-7a4e69e81da3","topicName":"Sinusitis","slug":"sinusitis","lastRevised":"Last revised in June 2018","chapters":[{"id":"2e4afda1-e9d5-5296-a027-01f4617ab6d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"405b3d6d-e395-5fea-bc5e-02ddf80a8bd2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"22d307e8-3756-562c-b49a-55d20a9d0c5d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"36290f8d-5730-5655-8fa4-0d3f584a2980","slug":"changes","fullItemName":"Changes"},{"id":"b0ba5cc8-0ed6-52d6-86c5-12833f47d8d3","slug":"update","fullItemName":"Update"}]},{"id":"f730377b-2158-527d-b9a1-e99c0653afd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5f96218a-0038-5b66-8c21-7db2d19f37b7","slug":"goals","fullItemName":"Goals"},{"id":"f4318fc5-fa1f-52cc-964f-2eeb9d4f7a27","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5a355772-1fc0-5033-929c-388a6956d7f5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"41d933ba-5f60-5f51-9a18-8d60f08747d9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"de2c52a0-2248-5977-a8e4-e495835a4f71","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"87fd2967-db43-5938-a83c-4761cd508da1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6b9273f7-5c2c-5994-a3d4-8617be04677e","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"62fda2cc-020c-5dda-8886-be553f1b04bc","slug":"definition","fullItemName":"Definition"},{"id":"d0ca7ab5-8889-52dd-8ac6-bcf949adf403","slug":"causes","fullItemName":"Causes"},{"id":"6c331f3e-5cee-537d-9ff6-41dba5324ae1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2b91bcbf-5ce3-5cdb-bb8d-03f4297a60fc","slug":"complications","fullItemName":"Complications"}]},{"id":"17787dc5-901a-5bd4-93f1-b3bd7830f0a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a3d013cf-b195-59ed-ac16-d0dc956a2637","slug":"diagnosis-acute-sinusitis","fullItemName":"Diagnosis - acute sinusitis"},{"id":"35be5a2e-61f3-5478-b238-c91020678ab0","slug":"diagnosis-chronic-sinusitis","fullItemName":"Diagnosis - chronic sinusitis"},{"id":"3ec7ffd9-5556-5eb7-9e51-14b4e1403c11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a5e0292f-f277-5859-bf17-fe0b4557eae3","fullItemName":"Management","slug":"management","subChapters":[{"id":"851420e1-952f-58e9-bb2d-b69ed5134584","slug":"acute-sinusitis","fullItemName":"Scenario: Acute sinusitis"},{"id":"fe33ee40-93d8-59ba-b62a-2f9ccc74cc63","slug":"chronic-sinusitis","fullItemName":"Scenario: Chronic sinusitis"}]},{"id":"ccbcf182-fe04-59e6-abdc-75557dc3c700","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bc9974c3-e759-5746-8c96-b4538af16946","slug":"analgesia","fullItemName":"Analgesia"},{"id":"b7e24d48-87af-5f2c-9097-f4e3b1de894d","slug":"nasal-corticosteroids","fullItemName":"Nasal corticosteroids"},{"id":"5f63c8f8-0eaa-5fe0-b473-2d5e3aef00d1","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"0d802baf-8d25-5d8a-9c6d-b2a448983e4a","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"e874a37b-5cc8-58c8-9335-ac01e3b17271","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"bb4fef09-b30c-5637-ae85-ba203f26acd9","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"827f1e92-8727-5460-b9ae-00929701cc77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dbc93c2-6562-533b-8dd9-0891fc35822e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b0f7242-5fbb-5eb4-8b1a-13af5d4383df","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a3d9d72-ed21-52d6-ba45-abcfb27ec6b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1b69a1e4-ec7f-5483-873c-2bb4bfb1345c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f04034ff-dd83-5bf5-83de-77fe9877df85","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f54f59b3-2893-5e4b-8dd2-3bee521cb237","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"164a0943-7f01-50bd-8c8f-a3695b72b662","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ccbcf182-fe04-59e6-abdc-75557dc3c700","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3a0ea632-a6f8-54f2-af07-c9a1b4a1c716","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field c0684c2b-d04a-4672-bea1-a8e800b72a97 --><h3>Cautions and contraindications</h3><!-- end field c0684c2b-d04a-4672-bea1-a8e800b72a97 -->","summary":"","htmlStringContent":"<!-- begin item 536164de-a98d-4d18-af97-a8e800b729b1 --><!-- begin field 2354bff7-8a8a-456f-bee6-a8e800b72a97 --><ul><li><strong>Do not prescribe clarithromycin in people:</strong><ul><li>Taking drugs that prolong the QT interval (for example, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li><li>With hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>With severe hepatic impairment if they also have renal impairment.</li></ul></li><li><strong>Prescribe clarithromycin with caution in people with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Electrolyte disturbances, such as hypomagnesaemia.</li><li>Impaired hepatic function – clarithromycin is principally excreted by the liver.</li><li>Myasthenia gravis — macrolides may aggravate symptoms.</li><li>Severe renal impairment (eGFR less than 30 mL/min/1.73m<sup>2</sup>).<ul><li>Use half the normal dose. Avoid Klaricid XL<sup>® </sup>(clarithromycin prolonged-release once daily tablets) as the dose cannot be reduced.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">FDA, 2018</a>]</p><!-- end field 2354bff7-8a8a-456f-bee6-a8e800b72a97 --><!-- end item 536164de-a98d-4d18-af97-a8e800b729b1 -->","subChapters":[]},{"id":"b7a7c9d1-69d9-57de-8ab8-82906b0e8a3c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b6a2e628-f2c0-491c-8c7c-a8e800b749be --><h3>Adverse effects</h3><!-- end field b6a2e628-f2c0-491c-8c7c-a8e800b749be -->","summary":"","htmlStringContent":"<!-- begin item a35baaaa-318d-45db-afbc-a8e800b744f2 --><!-- begin field 60953bb2-422a-484f-a773-a8e800b749be --><ul><li><strong>Gastrointestinal</strong> — diarrhoea, vomiting, dyspepsia, nausea, abdominal pain (common).<ul><li><strong>Rarely: </strong>pancreatitis, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>. </li></ul></li><li><strong>Nervous system</strong> — headache, dysgeusia (common), dizziness, somnolence, tremor (uncommon).<ul><li><strong>Rarely:</strong> convulsions, paraesthesia.</li></ul></li><li><strong>Psychiatric</strong> — insomnia (common), anxiety, nervousness (uncommon).<ul><li><strong>Rarely or very rarely: </strong>psychotic disorders, depression, mania, hallucination.</li></ul></li><li><strong>Skin</strong> — rash, hyperhidrosis (common), pruritus, urticaria (uncommon).<ul><li><strong>Rarely, or very rarely:</strong> Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens Johnson syndrome, toxic epidermal necrolysis.</li></ul></li><li><strong>Other adverse effects reported rarely, or very rarely, include:</strong> <ul><li>Anaphylaxis.</li><li>Arrhythmias.</li><li>Deafness.</li><li>Hepatic failure, jaundice.</li><li>Pancreatitis. </li><li>QT interval prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field 60953bb2-422a-484f-a773-a8e800b749be --><!-- end item a35baaaa-318d-45db-afbc-a8e800b744f2 -->","subChapters":[]},{"id":"633e310c-386c-5b5c-bb61-ce3621a7485b","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 161bdf0c-097d-4db7-92cf-a8e800b7664e --><h3>Drug interactions</h3><!-- end field 161bdf0c-097d-4db7-92cf-a8e800b7664e -->","summary":"","htmlStringContent":"<!-- begin item 09229798-c3ed-471d-ac51-a8e800b765a1 --><!-- begin field f0181226-2af5-4b85-adc3-a8e800b7664e --><ul><li><strong>Calcium channel blockers (CCBs) </strong>— there is an increased risk of hypotension if CCBs, such as verapamil, amlodipine, and diltiazem are taken concomitantly with clarithromycin, as they are metabolised by CYP3A4. This may also lead to increased levels of clarithromycin.</li><li><strong>Ciclosporin —</strong> clarithromycin can increase ciclosporin levels. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Colchicine</strong> — colchicine toxicity has been reported with concomitant use of clarithromycin so the combination is contraindicated.</li><li><strong>CYP3A enzyme inducers </strong>(rifampicin, carbamazepine, phenobarbital) — these may induce the metabolism of clarithromycin, resulting in sub-therapeutic levels.<ul><li>It may be necessary to monitor the levels of these drugs, as CYP3A is inhibited by clarithromycin leading to higher plasma levels of the inducer.</li></ul></li><li><strong>Digoxin</strong> — clarithromycin increases digoxin levels. Monitor and reduce the digoxin dose if required.</li><li><strong>Edoxaban </strong>— levels may be increased by clarithromycin. </li><li><strong>Ergot alkaloids</strong> — concomitant administration is contraindicated, due to the risk of acute ergot toxicity.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised that if diarrhoea, vomiting or breakthrough bleeding occur there is a possibility of contraceptive failure. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Oral hypoglycaemic drugs (sulfonylureas) and insulin </strong>— the concomitant use of clarithromycin and oral hypoglycaemic drugs and/or insulin can result in significant hypoglycaemia. Monitor glucose levels.</li><li><strong>Statins (atorvastatin, simvastatin) </strong>— these are extensively metabolised by CYP3A4. Concomitant administration with clarithromycin increases the plasma levels.<ul><li>Simvastatin — do not prescribe clarithromycin to a person taking simvastatin. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin temporarily.</li><li>Atorvastatin — avoid concurrent use with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin.</li></ul></li><li><strong>Warfarin </strong>— clarithromycin increases the anticoagulant effect of warfarin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li><strong>Drugs that prolong the QT interval </strong>(such as amiodarone, or sotalol) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is contraindicated.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">FSRH, 2017</a>]</p><!-- end field f0181226-2af5-4b85-adc3-a8e800b7664e --><!-- end item 09229798-c3ed-471d-ac51-a8e800b765a1 -->","subChapters":[]},{"id":"7fa6a19a-7b7a-5ca7-a3b8-c4dbf7f7c24f","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field b38014a8-30a8-4c43-b872-a8e800b7e2f7 --><h3>Pregnancy and breastfeeding</h3><!-- end field b38014a8-30a8-4c43-b872-a8e800b7e2f7 -->","summary":"","htmlStringContent":"<!-- begin item 641fd35c-09e0-4c74-924c-a8e800b7e1a9 --><!-- begin field 60d79694-ce5b-40e7-8560-a8e800b7e2f7 --><h4>Pregnancy</h4><ul><li>The safety of clarithromycin in pregnancy has not been established. Avoid (especially in the first trimester), unless the benefit outweighs the risks.</li></ul><h4>Breastfeeding</h4><ul><li>Clarithromycin is excreted into breastmilk. Avoid use in women who are breastfeeding, unless the benefits outweigh the risks.</li><li>The risk of infantile hypertrophic pyloric stenosis in infants might be increased by the use of maternal macrolides especially in infants exposed in the first 2 weeks after birth.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">Fenner, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/sinusitis/references/\">BNF 75, 2018</a>]</p><!-- end field 60d79694-ce5b-40e7-8560-a8e800b7e2f7 --><!-- end item 641fd35c-09e0-4c74-924c-a8e800b7e1a9 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}